Lucid downgrades Passage Bio stock rating on funding concerns By Investing.com

Passage Bio was downgraded to Neutral from Buy, with Lucid Capital Markets cutting its price target to $9 from $68 as financing uncertainty around a pivotal PBFT02 study weighs on the outlook. The company also reported updated Phase 1/2 upliFT-D data showing 3.1% whole-brain atrophy at 12 months versus 8.7% in the ALLFTD natural history sample, a 64% reduction. Despite the clinical progress, the stock remains pressured by cash burn of about $32 million over the last 12 months and concerns about funding the registrational path.

Analysis

PASG has crossed from a science story into a financing story, which is usually where upside gets capped even when the data look directionally supportive. In microcap biotech, a credible path to a registrational study matters less for valuation than the ability to fund the runway to that inflection; once the market starts marking dilution probability higher, each incremental clinical de-risking tends to leak less into equity value than investors expect.

The second-order effect is that any upside from the updated clinical package may be partially transferred to future capital providers rather than current holders. If management has to finance into weakness, existing equity can experience a “good news, bad tape” dynamic where positive data tighten the eventual deal terms but do not rerate the stock until financing risk is removed. That also creates a competitive asymmetry: better-capitalized CNS gene-therapy programs can keep recruiting and advancing while PASG’s timeline risk stretches, making relative positioning more attractive than outright longs.

The main catalyst window is the next 1-2 quarters, not the next 1-2 years. Near term, the stock will trade on whether management can articulate a non-dilutive path or secure capital on tolerable terms; if not, the market will likely price in a raise well before the cash balance becomes critical. The contrarian view is that the current setup may be more interesting for a tactical long-volatility trade than a directional equity bet, because the stock can reprice sharply in either direction on financing headlines, FDA engagement, or additional data readouts.

Key Decisions for Investors

• Avoid initiating a fresh outright long in PASG here; the expected dilution overhang means the equity can underperform even if the clinical narrative stays constructive over the next 1-2 quarters.
• If already long PASG, trim into strength and retain a smaller core only into a clearly defined catalyst window; use a hard stop if financing language turns explicit or if the stock gaps on capital raise speculation.
• For event-driven traders, consider a limited-risk long straddle/strangle in PASG around the next company update or financing event; the setup is more attractive for volatility than direction because the stock can move 20-40% on headline risk.